A leading data and analytics company, GlobalData, reports that notwithstanding the withdrawal of promising ophthalmic pharmaceuticals from the clinical pipeline, the June 2018 Novartis spin-off of Alcon, and the rumors of Takeda selling Shire’s ophthalmic business, the ophtha market will continue to attract extensive R&D investment. Read More.